Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
0.931 USD | +4.21% | +7.80% | -45.07% |
May. 07 | Ginkgo Bioworks, GreenLab Launch Partnership to Produce Sugar Substitute Brazzein | MT |
May. 07 | GreenLab and Ginkgo Bioworks Announce New Partnership | CI |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 68% by 2026.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- The company appears highly valued given the size of its balance sheet.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-45.07% | 1.97B | B- | ||
+24.83% | 46.71B | B- | ||
+48.83% | 41.8B | A | ||
-1.25% | 41.52B | B | ||
-3.42% | 29.55B | C | ||
+10.58% | 25.78B | B- | ||
-21.05% | 19.26B | B | ||
+1.02% | 12.14B | B+ | ||
-3.43% | 12.08B | C+ | ||
+27.24% | 11.98B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- DNA Stock
- Ratings Ginkgo Bioworks Holdings, Inc.